Consists of caffeine, chlorpheniramine, paracetamol, phenylephrine
What is Caffeine (Zelfast)?
Caffeine (Zelfast) is a central nervous system stimulant. It works by stimulating the brain. Caffeine (Zelfast) is found naturally in foods and beverages such as coffee, tea, colas, energy and chocolate. Botanical sources of Caffeine (Zelfast) include kola nuts, guarana, and yerba mate. Caffeine (Zelfast) is also available in prescription and non-prescription medications.
Caffeine (Zelfast) is used to restore mental alertness or wakefulness during fatigue or drowsiness. Caffeine (Zelfast) is also found in some headache and migraine medications, in certain dietary supplements used for weight loss, and in many popular energy drinks.
Caffeine (Zelfast) (Caffeine (Zelfast)) is available by prescription only. It is used for short-term treatment of neonatal apnea (breathing problems).
Caffeine (Zelfast) may also be used for other conditions as determined by your health care provider.
Caffeine (Zelfast) indications
Caffeine (Zelfast) and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe Caffeine (Zelfast) and other analeptics should not be used in these conditions and recommend other supportive therapy.
How should I use Caffeine (Zelfast)?
Use Caffeine (Zelfast) as directed by your health care provider. If the medication is OTC, check the label on the bottle for the exact dosing instructions. If you have any questions about the use of an OTC medication, ask your pharmacist.
- Caffeine (Zelfast) may be taken with or without food. If Caffeine (Zelfast) upsets your stomach, take it with food.
- Do not exceed the recommended dose of Caffeine (Zelfast). Caffeine (Zelfast) can be habit-forming.
- Most OTC medications used for mental alertness contain 200 milligrams of Caffeine (Zelfast) per tablet or capsule. The usual maximum recommended dose of OTC Caffeine (Zelfast) is no more than 200 mg every 3-4 hours, or 1600 mg per day.
- Do not double-up on your Caffeine (Zelfast) dose if you should miss the time for next dose.
- The average cup of coffee contains 150-200 milligrams (mg) of Caffeine (Zelfast) per cup, while a cup of tea will have about 60 mg of Caffeine (Zelfast). Cola products have about 30-40 mg of Caffeine (Zelfast), and most energy drinks have about 60-70 mg. Be sure to account for any dietary Caffeine (Zelfast) that is consumed.
Ask your health care provider any questions you may have about how to use Caffeine (Zelfast).
Uses of Caffeine (Zelfast) in details
Use: Labeled Indications
Caffeine (Zelfast): Treatment of idiopathic apnea of prematurity
Caffeine (Zelfast) and sodium benzoate: See Off-Label uses.
Caffeine (Zelfast) [OTC labeling]: Restore mental alertness or wakefulness when experiencing fatigue
Off Label Uses
Augmentation of seizure induction during electroconvulsive therapy (Caffeine (Zelfast) and sodium benzoate)
Data from a randomized, double blind study as well as a few unblinded studies support the use of Caffeine (Zelfast)/sodium benzoate in the treatment of augmentation of seizure induction during electroconvulsive therapy (ECT).
Caffeine (Zelfast) description
A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine (Zelfast)'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of Caffeine (Zelfast) have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [PubChem]
Caffeine (Zelfast) dosage
Usual Adult Dose for Drowsiness:
100 to 200 mg orally not more often than every 3 to 4 hours.
For occasional use only.
Not intended for use as a substitute for sleep.
Limit the use of Caffeine (Zelfast) containing medications, foods, or beverages while taking this product because too much Caffeine (Zelfast) may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.
Usual Pediatric Dose for Drowsiness:
>= 12 years: 100 to 200 mg not more often than every 3 to 4 hours.
For occasional use only.
Not intended for use as a substitute for sleep.
Limit the use of Caffeine (Zelfast) containing medications, foods, or beverages while taking this product because too much Caffeine (Zelfast) may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.
Usual Pediatric Dose for Apnea of Prematurity:
For short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.
Prior to initiation of Caffeine (Zelfast), baseline serum levels of Caffeine (Zelfast) should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to Caffeine (Zelfast). Likewise, baseline serum levels of Caffeine (Zelfast) should be measured in infants born to mothers who consumed Caffeine (Zelfast) prior to delivery, since Caffeine (Zelfast) readily crosses the placenta.
Loading Dose: 20 mg/kg Caffeine (Zelfast) intravenous (over 30 minutes) once
Maintenance Dose: 5 mg/kg Caffeine (Zelfast) intravenous (over 10 minutes) or orally every 24 hours.
Note: The dose of Caffeine (Zelfast) base is one-half the dose when expressed as Caffeine (Zelfast) (e.g., 20 mg of Caffeine (Zelfast) is equivalent to 10 mg of Caffeine (Zelfast) base).
Serum concentrations of Caffeine (Zelfast) may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.
Apnea of prematurity is a diagnosis of exclusion. Other causes of apnea (e.g., central nervous system disorders, primary lung disease, anemia, sepsis, metabolic disturbances, cardiovascular abnormalities, or obstructive apnea) should be ruled out or properly treated prior to initiation of Caffeine (Zelfast).
Caffeine (Zelfast) should be used with caution in infants with seizure disorders or cardiovascular disease.
The duration of treatment of apnea of prematurity in the placebo-controlled trial was limited to 10 to 12 days. The safety and efficacy of Caffeine (Zelfast) for longer periods of treatment have not been established.
Caffeine (Zelfast) interactions
See also:
What other drugs will affect Caffeine (Zelfast)?
Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination
Adenosine: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving Caffeine (Zelfast). Discontinue Caffeine (Zelfast) in advance of scheduled diagnostic use of adenosine whenever possible. Consider therapy modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
Bromperidol: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may decrease the absorption of Bromperidol. Monitor therapy
BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
CYP1A2 Inducers (Moderate): May decrease the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
CYP1A2 Inhibitors (Strong): May increase the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
Doxofylline: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the adverse/toxic effect of Doxofylline. Avoid combination
Esketamine: May enhance the hypertensive effect of CNS Stimulants. Monitor therapy
Formoterol: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the hypokalemic effect of Formoterol. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Indacaterol: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the hypokalemic effect of Indacaterol. Monitor therapy
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Lithium: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may decrease the serum concentration of Lithium. Monitor therapy
Norfloxacin: May increase the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
Olodaterol: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may enhance the hypokalemic effect of Olodaterol. Monitor therapy
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Pipemidic Acid: May increase the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
Regadenoson: Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using Caffeine (Zelfast) or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Consider therapy modification
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Stiripentol: May increase the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy
TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Consider therapy modification
Tobacco (Smoked): May decrease the serum concentration of Caffeine (Zelfast) and Caffeine (Zelfast) Containing Products. Monitor therapy
Caffeine (Zelfast) side effects
See also:
What are the possible side effects of Caffeine (Zelfast)?
Cardiovascular
Tachycardia; extrasystoles; palpitations; other cardiac arrhythmias.
CNS
Insomnia; restlessness; excitement; nervousness; tinnitus; scintillating scotoma; muscular tremor; headache; lightheadedness.
Dermatologic
Urticaria; rash, dry skin, skin breakdown (Caffeine (Zelfast)).
EENT
Retinopathy of prematurity (Caffeine (Zelfast)).
GI
Vomiting; nausea; diarrhea; stomach pain; necrotizing enterocolitis, gastritis, GI hemorrhage (Caffeine (Zelfast)).
Genitourinary
Diuresis; kidney failure (Caffeine (Zelfast)).
Hematologic
Disseminated intravascular coagulation (Caffeine (Zelfast)).
Metabolic
Hyperglycemia; acidosis (Caffeine (Zelfast)).
Respiratory
Dyspnea, lung edema (Caffeine (Zelfast)).
Miscellaneous
Hypersensitivity (eg, dermatitis, rhinitis, bronchial asthma); feeding intolerance, sepsis, accidental injury, hemorrhage, cerebral hemorrhage (Caffeine (Zelfast)).
Caffeine (Zelfast) contraindications
See also:
What is the most important information I should know about Caffeine (Zelfast)?
Caffeine (Zelfast) should not be given to a child who has had an allergic reaction to it in the past.
Before using Caffeine (Zelfast), tell the doctor if your child is allergic to any drugs, or has a seizure disorder, heart disease, kidney disease, liver disease, or high or low blood sugar.
Do not use the medication for longer than 12 days without the advice of your child's doctor.
Each bottle of Caffeine (Zelfast) is for one use only, even if your child does not use the entire bottle for a single dose. Throw away any medication left over in the bottle after measuring your child's dose.
Call your doctor if the child's breathing symptoms do not improve after using Caffeine (Zelfast).
To be sure Caffeine (Zelfast) is helping your child's condition, the child's blood will need to be tested on a regular basis. Do not miss any scheduled appointments.
What is Chlorpheniramine (Zelfast)?
Chlorpheniramine (Zelfast) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Chlorpheniramine (Zelfast) is used to treat runny nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu.
Chlorpheniramine (Zelfast) may also be used for purposes not listed in this medication guide.
Chlorpheniramine (Zelfast) indications
this medicine is indicated for symptomatic control of all allergic conditions responsive to antihistamines, including hay fever, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites.
Also indicated for the symptomatic relief of itch associated with chickenpox
How should I use Chlorpheniramine (Zelfast)?
Use Chlorpheniramine (Zelfast) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Chlorpheniramine (Zelfast) may be taken with or without food.
- Shake well before using.
- Use the dropper that comes with Chlorpheniramine (Zelfast) to measure your dose. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you miss a dose of Chlorpheniramine (Zelfast), take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Chlorpheniramine (Zelfast).
Uses of Chlorpheniramine (Zelfast) in details
Use: Labeled Indications
Allergic symptoms, allergic rhinitis, urticaria, pruritus: Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria, pruritus
Off Label Uses
Motion sickness
Data from a limited number of patients studied suggests that Chlorpheniramine (Zelfast) may be beneficial in the treatment of motion sickness. Additional data may be necessary to further define its role in this condition.
Chlorpheniramine (Zelfast) description
An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.
Chlorpheniramine (Zelfast) dosage
Chlorpheniramine (Zelfast) Dosage
Generic name: Chlorpheniramine (Zelfast) MALEATE 4mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
take every 4 to 6 hours, not more than 6 doses in 24 hours
adults and children 12 years of age and over | 1 tablet (4 mg) |
children 6 to under 12 years of age | 1/2 tablet (2 mg) |
children 4 to under 6 years of age | do not use unless directed by a doctor |
children under 4 years of age | do not use |
More about Chlorpheniramine (Zelfast) (Chlorpheniramine (Zelfast))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Other brands: Chlorpheniramine (Zelfast), Chlorpheniramine (Zelfast), Allergy Relief, Wal-finate, More (9) »
Professional resources
- Chlorpheniramine (Zelfast) (FDA)
Related treatment guides
- Allergic Reactions
- Allergic Rhinitis
- Cold Symptoms
- Urticaria
Chlorpheniramine (Zelfast) interactions
See also:
What other drugs will affect Chlorpheniramine (Zelfast)?
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray), antispasmodics (e.g., atropine, belladonna alkaloids), drugs for Parkinson's disease (e.g., anticholinergics such as benztropine, trihexyphenidyl), scopolamine, tricyclic antidepressants (e.g., amitriptyline).
Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as: certain antihistamines (e.g., diphenhydramine), anti-seizure drugs (e.g., carbamazepine), medicine for sleep or anxiety (e.g., alprazolam, diazepam, zolpidem), muscle relaxants, narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., chlorpromazine, risperidone, amitriptyline, trazodone). Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain drowsiness-causing ingredients. Ask your pharmacist about the safe use of those products.
Chlorpheniramine (Zelfast) is very similar to dexchlorpheniramine. Do not use medications containing dexchlorpheniramine while using Chlorpheniramine (Zelfast).
This medication may interfere with certain laboratory tests (including allergy skin testing), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
Chlorpheniramine (Zelfast) side effects
See also:
What are the possible side effects of Chlorpheniramine (Zelfast)?
Applies to Chlorpheniramine (Zelfast): capsules, controlled-release capsules, suspension drops, sustained-release capsules, syrup, tablets
Other dosage forms:
- suspension
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Seek medical attention right away if any of these SEVERE side effects occur while taking Chlorpheniramine (Zelfast) (the active ingredient contained in Chlorpheniramine (Zelfast) (Allergy))
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
Chlorpheniramine (Zelfast) contraindications
See also:
What is the most important information I should know about Chlorpheniramine (Zelfast)?
Hypersensitivity to Chlorpheniramine (Zelfast) maleate or any component of the formulation; narrow-angle glaucoma; bladder neck obstruction; symptomatic prostate hypertrophy; during acute asthmatic attacks; stenosing peptic ulcer; pyloroduodenal obstruction. Avoid use in premature and term newborns due to possible association with SIDS.
OTC labeling: When used for self-medication, do not use to make a child sleep
What is Paracetamol (Zelfast)?
Paracetamol (Zelfast) (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of Paracetamol (Zelfast) of is not known.
Paracetamol (Zelfast) is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.
Paracetamol (Zelfast) may also be used for other purposes not listed in this medication guide.
Paracetamol (Zelfast) indications
For systemic use of Paracetamol (Zelfast) Sante Naturelle: prevention and treatment of hypo- and avitaminosis of vitamin C; providing increased need for vitamin C during growth, pregnancy, lactation, with heavy loads, fatigue and during recovery after prolonged severe illness; in winter with an increased risk of infectious diseases.
For intravaginal use: chronic or recurrent vaginitis (bacterial vaginosis, nonspecific vaginitis) caused by the anaerobic flora (due to changes in pH of the vagina) in order to normalize disturbed vaginal microflora.
How should I use Paracetamol (Zelfast)?
Use Paracetamol (Zelfast) exactly as directed on the label, or as prescribed by your doctor.
Do not use more of this medication than is recommended. An overdose of Paracetamol (Zelfast) can cause serious harm. The maximum amount for adults is 1 gram (1000 mg) per dose and 4 grams (4000 mg) per day. Using more Paracetamol (Zelfast) could cause damage to your liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking Paracetamol (Zelfast) and never use more than 2 grams (2000 mg) per day. If you are treating a child, use a pediatric form of Paracetamol (Zelfast). Carefully follow the dosing directions on the medicine label. Do not give the medication to a child younger than 2 years old without the advice of a doctor.
Measure the liquid form of Paracetamol (Zelfast) with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. You may need to shake the liquid before each use. Follow the directions on the medicine label.
The Paracetamol (Zelfast) chewable tablet must be chewed thoroughly before you swallow it.
Make sure your hands are dry when handling the Paracetamol (Zelfast) disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.
To use the Paracetamol (Zelfast) effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.
Do not take a Paracetamol (Zelfast) rectal suppository by mouth. It is for use only in your rectum. Wash your hands before and after inserting the suppository.
Try to empty your bowel and bladder just before using the Paracetamol (Zelfast) suppository. Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands.
For best results from the suppository, lie down and insert the suppository pointed tip first into the rectum. Hold in the suppository for a few minutes. It will melt quickly once inserted and you should feel little or no discomfort while holding it in. Avoid using the bathroom just after inserting the suppository.
Stop using Paracetamol (Zelfast) and call your doctor if:
-
you still have a fever after 3 days of use;
-
you still have pain after 7 days of use (or 5 days if treating a child);
-
you have a skin rash, ongoing headache, or any redness or swelling; or
-
if your symptoms get worse, or if you have any new symptoms.
Urine glucose tests may produce false results while you are taking Paracetamol (Zelfast). Talk to your doctor if you are diabetic and you notice changes in your glucose levels during treatment.
Store Paracetamol (Zelfast) at room temperature away from heat and moisture. The rectal suppositories can be stored at room temperature or in the refrigerator.
Uses of Paracetamol (Zelfast) in details
This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.
How to use Paracetamol (Zelfast)
Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.
If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.
For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.
For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.
Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.
For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.
Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.
Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.
Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.
Paracetamol (Zelfast) description
Paracetamol (Zelfast) is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Paracetamol (Zelfast) exists as small alkaline deliquescent crystals with a saline tasteacinol was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successfulacinol was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic Paracetamol (Zelfast). Their mode of Paracetamol (Zelfast) is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.
Paracetamol (Zelfast) dosage
Usual Adult Paracetamol (Zelfast) Dose for Fever:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Zelfast) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Adult Paracetamol (Zelfast) Dose for Pain:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Zelfast) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Pediatric Dose for Fever:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
Usual Pediatric Dose for Pain:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
Paracetamol (Zelfast) interactions
See also:
What other drugs will affect Paracetamol (Zelfast)?
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic Paracetamol (Zelfast) of Paracetamol (Zelfast).
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Zelfast).
With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Zelfast) from the body and may reduce its analgesic Paracetamol (Zelfast).
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Zelfast).
When Paracetamol (Zelfast) applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Zelfast). A case of severe toxic liver injury.
Described cases of toxic effects of Paracetamol (Zelfast), while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Zelfast), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Zelfast) and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Zelfast) may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Zelfast) and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of Paracetamol (Zelfast), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Zelfast) due to increasing its metabolism in the liver.
At simultaneous application of Paracetamol (Zelfast) with ethinylestradiol increases absorption of Paracetamol (Zelfast) from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of Paracetamol (Zelfast) increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
Paracetamol (Zelfast) side effects
See also:
What are the possible side effects of Paracetamol (Zelfast)?
Effects due to the presence of acetylsalicylic acid.
Accidents awareness with respiratory or skin reactions (angioedema, urticaria, asthma, anaphylactic shock);
Cross hypersensitivity reactions with NSAIDs and with tartrazine;
At low doses recommended for the use of Paracetamol (Zelfast), side effects of aspirin are generally limited to some irritation of the gastro-intestinal tract.
At higher doses, side effects include gastrointestinal mucosal erosions, gastric ulcer or duodenal ulcer, occult blood loss, melena.
Acetylsalicylic acid may also increase the tendency to bleeding and bleeding time (the lengthening of bleeding continues 4-6 days after stopping the drug).
It may also worsen renal function including cases of pre-existing condition (the long-term use can cause chronic kidney disease).
The signs of salicylic overdose described under.
Effects due to the presence of Paracetamol (Zelfast).
At the doses and duration of recommended treatment, side effects are usually negligible, but the prolonged use of Paracetamol (Zelfast) in therapeutic doses large (2-4 g per day, or 10-20 tablets Paracetamol (Zelfast)) may cause the appearance chronic hepatitis. This justifies the recommendations of caution especially in patients with liver disease prior.
Very rarely, it can produce thrombocytopenia.
The acute liver toxicity in overdose massive (doses greater than 8 g of Paracetamol (Zelfast)) is described in paragraph overdose.
Paracetamol (Zelfast) contraindications
See also:
What is the most important information I should know about Paracetamol (Zelfast)?
Paracetamol (Zelfast) should not be used in patients who have previously exhibited hypersensitivity to aspirin and/or nonsteroidal antiinflammatory agents. Paracetamol (Zelfast) should not be given to patients with a recent history of gastrointestinal bleeding or in patients with bleeding disorders (e.g., hemophilia).
What is Phenylephrine (Zelfast)?
Phenylephrine (Zelfast) (Phenylephrine (Zelfast)) is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
Phenylephrine (Zelfast) is used to treat nasal and sinus congestion, or congestion of the tubes that drain fluid from your inner ears, called the eustachian (yoo-STAY-shun) tubes.
Phenylephrine (Zelfast) may also be used for purposes not listed in this medication guide.
Phenylephrine (Zelfast) indications
Phenylephrine (Zelfast) is used for the temporary relief of stuffy nose, sinus, and ear symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis). This medication works by decreasing swelling in the nose and ears, thereby lessening discomfort and making it easier to breathe.
Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.
How should I use Phenylephrine (Zelfast)?
Use Phenylephrine (Zelfast) drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Phenylephrine (Zelfast) drops is for use in the eye only. Avoid contact with the nose or mouth.
- To use Phenylephrine (Zelfast) drops, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.
- Do not wear contact lenses while you are using Phenylephrine (Zelfast) drops. Sterilize contact lenses according to the manufacturer's directions and check with your doctor before using them.
- Do not use Phenylephrine (Zelfast) drops if it is brown or contains particles.
- If you miss a dose of Phenylephrine (Zelfast) drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Phenylephrine (Zelfast) drops.
Uses of Phenylephrine (Zelfast) in details
Use: Labeled Indications
Hypotension/shock: Treatment of hypotension, vascular failure in shock. Note: Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).
Guideline recommendations:
Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends Phenylephrine (Zelfast), if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).
Hypotension during anesthesia: As a vasoconstrictor in regional analgesia
Nasal congestion: As a decongestant [OTC]
Off Label Uses
Hypotension in patients with obstructive hypertrophic cardiomyopathy
Phenylephrine (Zelfast) is a pure alpha1 agonist that will increase systemic vascular resistance without increasing heart rate or contractility. This is advantageous in patients with obstructive hypertrophic cardiomyopathy and hypotension since increases in both heart rate and contractility may cause the obstruction to worsen, leading to a decrease in cardiac output. Other vasopressors like dopamine, epinephrine, and norepinephrine may increase contractility and/or heart rate. Additional trials may be necessary to further define the role of Phenylephrine (Zelfast) in this condition.
Based on the American Urological Association guidelines for the management of priapism, due to the low risk of cardiovascular side effects intracavernous injection of Phenylephrine (Zelfast) is recommended for ischemic priapism that persists following aspiration/irrigation.
Phenylephrine (Zelfast) description
Phenylephrine (Zelfast) is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Phenylephrine (Zelfast) dosage
Phenylephrine (Zelfast) Dosage
Generic name: Phenylephrine (Zelfast) HYDROCHLORIDE 10mg in 1mL
Dosage form: injection
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
General Dosage and Administration Instructions
Phenylephrine (Zelfast) (Phenylephrine (Zelfast) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
- Bolus: Dilute with normal saline or 5% dextrose in water.
- Continuous infusion: Dilute with normal saline or 5% dextrose in water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During Phenylephrine (Zelfast) administration:
- Correct intravascular volume depletion.
- Correct acidosis. Acidosis may reduce the effectiveness of Phenylephrine (Zelfast).
Dosing for Treatment of Hypotension during Anesthesia
The following are the recommended dosages for the treatment of hypotension during anesthesia.
- The recommended initial dose is 40 to 100 mcg administered by intravenous bolus. May administer additional boluses every 1-2 minutes as needed; not to exceed a total dosage of 200 mcg.
- If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.
- Adjust dosage according to the blood pressure goal.
Prepare a 100 mcg/mL Solution for Bolus
Intravenous Administration
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Zelfast):
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Zelfast) and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
- Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
Prepare a Solution for Continuous
Intravenous Administration
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Zelfast) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Zelfast) and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
Directions for Dispensing from Pharmacy Bulk Vial
The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.
More about Phenylephrine (Zelfast) (Phenylephrine (Zelfast))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Phenylephrine (Zelfast)
- Phenylephrine (Zelfast) (Advanced Reading)
- Other brands: Neo-Synephrine, Phenylephrine (Zelfast) Congestion, Sudogest PE, Phenylephrine (Zelfast) Children's Nasal Decongestant, More (9) »
Professional resources
- Phenylephrine (Zelfast) (FDA)
- Phenylephrine (Zelfast) Hydrochloride (AHFS Monograph)
Related treatment guides
- Hypotension
Phenylephrine (Zelfast) interactions
See also:
What other drugs will affect Phenylephrine (Zelfast)?
Acetaminophen: May increase the serum concentration of Phenylephrine (Zelfast) (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Zelfast) (Systemic). Monitor therapy
CloZAPine: May diminish the therapeutic effect of Phenylephrine (Zelfast) (Systemic). Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Zelfast) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Zelfast). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Zelfast) may be considered as clinically indicated. Avoid combination
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Ioflupane I 123: Phenylephrine (Zelfast) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Propacetamol: May increase the serum concentration of Phenylephrine (Zelfast) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Zelfast) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
Phenylephrine (Zelfast) side effects
See also:
What are the possible side effects of Phenylephrine (Zelfast)?
Applies to Phenylephrine (Zelfast): intravenous solution
As well as its needed effects, Phenylephrine (Zelfast) (the active ingredient contained in Phenylephrine (Zelfast)) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking Phenylephrine (Zelfast), check with your doctor or nurse immediately:
Incidence not known:
- Blurred vision
- chest pain or discomfort
- difficult or labored breathing
- dizziness
- fainting
- fast, slow, or irregular heartbeat
- headache
- nausea or vomiting
- nervousness
- pain in the shoulders, arms, jaw, or neck
- pounding in the ears
- sweating
- tightness in the chest
- unusual tiredness
If any of the following symptoms of overdose occur while taking Phenylephrine (Zelfast), get emergency help immediately:
Symptoms of overdose:
- Feeling of fullness in the head
- pounding or rapid pulse
- tingling in the arms or legs
- vomiting
Minor Side Effects
Some Phenylephrine (Zelfast) side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Incidence not known:
- Heartburn
- itching skin
- nausea
- pain in the neck
- pain or discomfort in chest, upper stomach, or throat
Phenylephrine (Zelfast) contraindications
See also:
What is the most important information I should know about Phenylephrine (Zelfast)?
Minims Phenylephrine (Zelfast) hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it or to any of the components.
Active ingredient matches for Zelfast:
Caffeine/chlorpheniramine/paracetamol/phenylephrine in India.
Unit description / dosage (Manufacturer) | Price, USD |
10's | |
Zelfast Phenylephrine 5 mg, Chlorpheniramine 4 mg, Caffeine 30 mg, Paracetamol500 mg. TAB / 10 | |
ZELFAST tab 10's (Rouzel) | |
Zelfast Phenylephrine 5 mg, Chlorpheniramine 4 mg, Caffeine 30 mg, Paracetamol500 mg. TAB / 10 | |
List of Zelfast substitutes (brand and generic names): | |
Triaminic Toddler Congestion Thin Strips | |
Triaminic Toddler Congestion Thin Strips strip 2.5 mg (Novartis Consumer Health Canada Inc. (Canada)) | |
Trigenic CS | |
Trigenic CS 60 ml Syrup (Trigenesis Lifesciences Pvt. Ltd.) | $ 0.03 |
Tromide Plus | |
Tromide Plus Eye 5 ml Drop (Entod Pharmaceuticals Ltd) | $ 0.11 |
Tromide Plus Eye 3 ml Drop (Entod Pharmaceuticals Ltd) | $ 0.16 |
TROMIDE PLUS 5%/0.8% EYE DROPS 1 packet / 5 ML eye drop each (Entod Pharmaceuticals Ltd) | $ 0.58 |
Tromide Plus 5% w/v/0.8% w/v Eye Drop (Entod Pharmaceuticals Ltd) | $ 0.58 |
Tropifrin | |
Tropifrin Eye 3 ml Drop (Jawa Pharmaceuticals (India) Pvt. Ltd.) | $ 0.11 |
TROPIFRIN 5%/0.8% EYE DROPS 1 packet / 3 ML eye drop each (Jawa Pharmaceuticals (India) Pvt. Ltd.) | $ 0.74 |
TROPIFRIN 5%W/V/0.8%W/V EYE DROPS 1 packet / 5 ML eye drop each (Jawa Pharmaceuticals (India) Pvt. Ltd.) | $ 0.82 |
Tropifrin 5% w/v/0.8% w/v Eye Drop (Jawa Pharmaceuticals (India) Pvt. Ltd.) | $ 0.74 |
Tropifrin 5% w/v/0.8 (Jawa Pharmaceuticals (India) Pvt. Ltd.) | $ 0.82 |
TRUSTYL-COLD (India) | |
60ml (AHPL) | $ 0.33 |
Trustyl-Cold Phenylephrine 2.5 mg, Paracetamol 125 mg, Chlorpheniramine maleate 1mg/5 mL. SYR / 60ml (AHPL) | $ 0.33 |
TRUSTYL-COLD syr 60ml (AHPL) | $ 0.36 |
Trustyl-Cold Phenylephrine 2.5 mg, Paracetamol 125 mg, Chlorpheniramine maleate 1mg/5 mL. SYR / 60ml (AHPL) | $ 0.33 |
Tur-Bi-Cal | |
Unicold-S (India) | |
Unicold-S Cetirizine 2.5 mg, paracetamol12.5 mg, phenylephrinehydrochloride 5 mg. O-SUSP / 60ml (Unikind) | $ 0.42 |
UNICOLD-S oral susp 60ml (Unikind) | $ 0.42 |
Uroflam Forte (Peru) | |
Vazculep | |
Vazculep injection 10 mg/mL (Eclat Pharmaceuticals, LLC (US)) | |
Venmol Plus Tablet | |
Venmol Plus Tablet (Vencare Formulations Pvt Ltd) | $ 0.02 |
Ventirex C | |
Ventirex C 100 ml Syrup (Unimarck Pharma (India) Limited) | $ 0.03 |
Ventirex C 2.5 mg/30 mg Syrup (Unimarck Pharma (India) Limited) | $ 0.61 |
Vibrocil Microdosificador (Peru) | |
Vibrocilfen (Portugal) | |
Vinkold (India) | |
Vinkold Cetirizine dihydrochloride 5mg, paracetamol 500 mg, phenylephrine 10 mg TAB / 10 (Vinca) | $ 0.29 |
VINKOLD tab 10's (Vinca) | $ 0.29 |
Visadron (Austria, Bahrain, Belgium, Cyprus, Egypt, Germany, Iraq, Jordan, Kenya, Kuwait, Lebanon, Libya, Luxembourg, Netherlands, Portugal, Qatar, Saudi Arabia, Spain, Sudan, United Arab Emirates, Yemen) | |
Drops; Ophthalmic; Phenylephrine Hydrochloride (Alcon) | |
Visopt (Australia) | |
Vistafrin (Spain) | |
Vistosan (Germany) | |
Vital Eyes (United States) | |
Wei Li Ang (China) | |
Weiscalina (Mexico) | |
XYKAA PLUS | |
YASHCOLD | |
Zedex Cold (India) | |
Zedex Cold Paracetamol 125 mg, phenylephrine 5 mg, chlorpheniramine maleate 1 mg, sodium citrate 60 mg, menthol1 mg. SYR / 60ml (Wockhardt (Spectra)) | |
ZEDEX COLD 125 MG/5ML/5 MG/5ML SYRUP 1 bottle / 60 ML syrup each (Wockhardt (Spectra)) | $ 0.46 |
ZEDEX COLD syr 60ml (Wockhardt (Spectra)) | $ 0.42 |
Zedex Cold 125mg/5ml/5mg/ml Syrup (Wockhardt (Spectra)) | $ 0.46 |
Zednic | |
Zednic 60 ml Suspension (Zedchem Pharma) | $ 0.04 |
See 956 substitutes for Zelfast |
References
- DailyMed. "CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "phenylephrine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Zelfast are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Zelfast. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Zelfast before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 2 days and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Zelfast. To get the time effectiveness of using Zelfast drug by other patients, please click here.
Users | % | ||
---|---|---|---|
2 days | 1 | 100.0% |
5 consumers reported age
Users | % | ||
---|---|---|---|
1-5 | 2 | 40.0% | |
6-15 | 2 | 40.0% | |
46-60 | 1 | 20.0% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology